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Background: Diarrhoeal disease is a major global health problem, particularly affecting children under the age of 5
years. Besides oral rehydration solution, probiotics are also commonly prescribed to children with acute watery
diarrhoea in some settings. Results from randomised clinical trials (RCTs) in which investigators studied the effect of
probiotics on diarrhoeal symptoms have largely shown a positive effect; yet, the overall quality of the data is limited. In
Vietnam, probiotics are the most frequently prescribed treatment for children hospitalised with acute watery diarrhoea,
but there is little justification for this treatment in this location. We have designed a RCT to test the hypothesis that an
oral preparation of Lactobacillus acidophilus is superior to placebo in the treatment of acute watery diarrhoea in
Vietnamese children.
Methods: This RCT was designed to study the effect of treatment with L. acidophilus (4 × 109 colony-forming units/
day) for 5 days for acute watery diarrhoea against a placebo in 300 children ages 9 to 60 months admitted to hospitals
in Vietnam. Clinical and laboratory data plus samples will be collected on admission, daily during hospitalisation, at
discharge, and at follow-up visits for a subset of participants. The primary end point will be defined as the time from
the first dose of study medication to the start of the first 24-hour period without diarrhoea as assessed by the on-duty
nurse. Secondary endpoints include the time to cessation of diarrhoea as recorded by parents or guardians in an hourly
checklist, stool frequency over the first 3 days, treatment failure, rotavirus and norovirus viral loads, and adverse events.
Discussion: The existing evidence for the use of probiotics in treating acute watery diarrhoea seems to favour their
use. However, the size of the effect varies across publications. An array of different probiotic organisms, doses,
treatment durations, study populations, designs, settings, and aetiologies have been described. In this trial, we will
investigate whether probiotics are beneficial as an adjuvant treatment for children with acute watery diarrhoea in
Vietnam, with the aim of guiding clinical practice through improved regional evidence.
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Diarrhoeal disease is a global health issue, yet the vast
burden is in young children in developing countries [1].
In 2010, more than 7 million children younger than 5
years old died, and 15% of these deaths were attributed
to diarrhoea [2,3]. Typically, diarrhoeal episodes are self-
limiting, and patients often recover without receiving an
aetiological diagnosis. In those who are diagnosed, rota-
virus is the most frequently identified pathogen, followed
by a multitude of other viral, parasitic and bacterial
agents [4]. Vietnam is a rapidly developing country in
Southeast Asia, with an estimated mortality rate of 23
per 1,000 live births among children younger than 5
years old [2]. The number of deaths in children in this
key age bracket in Vietnam in 2010 was 34,940, 11% of
which were attributable to diarrhoeal infections [3].
Oral rehydration solution (ORS), zinc and antimicro-
bials are the main treatments for acute diarrhoea in chil-
dren in Vietnam [5]. During a cross-sectional study of
approximately 1,500 children hospitalised with diar-
rhoea, however, we found that 11% of diarrhoeal patients
were given probiotics prior to hospitalisation, and 71%
of children were prescribed probiotics during hospital-
isation (Phan Vu Tra My et al., unpublished manu-
script). Probiotics are preparations of bacteria and yeasts
that are considered to confer a beneficial health effect
when taken in an adequate amount [6]. Probiotics have
been studied extensively for their effects in preventing
and treating a multitude of conditions, including the
treatment of lactose intolerance, traveller’s diarrhoea and
the prevention and treatment of nosocomial diarrhoea
[7-10]. In acute diarrhoea, a reduction in the frequency
of diarrhoeal symptoms has been reported in adults and
children treated with probiotics. This cessation of diar-
rhoeal symptoms has been observed specifically in
patients with rotavirus, in those treated during the early
stages of a disease episode, and in those treated with
Lactobacillus spp. [11-14]. Investigators in previous trials
have evaluated the effect of probiotic colonisation on
rotavirus and found a potential reduction in rotavirus-
shedding in cohorts of Taiwanese, Polish and Italian
children [15-17]. Probiotics are well-tolerated; adverse
events (AEs) are rare and generally occur in patients
with underlying chronic diseases or in those on im-
munosuppressive therapy [18,19].
In a Cochrane review of the effect of probiotics for the
treatment of acute watery diarrhoea, Allen et al. com-
bined data from 8,014 participants in 63 studies [20].
The authors noted extensive heterogeneity in study
design, definitions, infecting agents, probiotic organisms
and dosage. Notwithstanding these caveats, the meta-
analysis found probiotics to be effective in reducing the
duration of diarrhoea by a mean of 24.76 hours
(95% confidence interval (CI) = 15.9 to 33.6 hours)compared to patients who either did not receive probio-
tics or were given a placebo. On the basis of these same
analyses, probiotic therapy was found to reduce the fre-
quency of stools on the second day of treatment by a
mean of 0.8 stools (95% CI = 0.45 to 1.14), and it reduced
the risk of developing persistent diarrhoea by 59% (95% CI
for risk ratio = 0.32 to 0.53). `The authors recommended
the design of larger, more robust trials specifically focusing
on pathogen identification and the incorporation of stand-
ard definitions and end points to inform clinical guidelines.
There is currently no international regulatory agreement
for the manufacturing or the clinical use of probiotics, and
there are different levels of scientific evidence required to
substantiate the health benefits of probiotics [21-23]. This
evidence is dependent on the product, the specific disease
effects, the strain and the dose. Additionally, probiotics can
be classified as either food additives or drugs, depending on
the local regulatory authority. This discrepancy has led to
interchangeable and often nonstandardised therapeutic use.
Therefore, trials incorporating the recommendations from
Allen et al. [20] to investigate the effects of probiotics for
acute diarrhoea are vital to increase the evidence base for
the use of probiotics as a clinical therapy in similar settings.
Methods/design
Study aims
We hypothesise that L. acidophilus is superior to no
L. acidophilus in the treatment of children admitted to the
hospital for acute watery diarrhoea in Ho Chi Minh City,
Vietnam. We will test this hypothesis by comparing an oral
daily dose of 4 × 109 colony-forming units (CFUs) of
L. acidophilus against placebo in children hospitalised with
acute diarrhoea. The study design presented herein aims to
investigate whether probiotic therapy with L. acidophilus
should be used as an appropriate and efficacious adjuvant
to ORS and zinc in treating children hospitalised with acute
watery diarrhoea. Using these data, we additionally aim to
inform local clinical practice on the use of probiotics for
treating acute diarrhoea by improving the quality of clinical
evidence.
Study design
This study is a multicentre, randomised, double-blind,
placebo-controlled trial designed to assess the effect of
adjunctive probiotic (L. acidophilus) therapy in children
admitted to the hospital with acute watery diarrhoea. La-
boratory endpoints from admission until discharge will
be recorded, and colonisation will be assessed in an out-
patient follow-up visit with the first 50 subjects who
agree to prolonged participation.
Eligibility
To be eligible for enrolment, patients will need to be
between 9 and 60 months of age and require hospitalisation
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history of less than 3 days, and written informed consent
from a parent or guardian will be required. This age group
was selected, as healthy children younger than 9 months of
age have less solid stools than those in an older age cat-
egory, making the cessation of diarrhoeal symptoms more
difficult to assess. Diarrhoea in this study is defined accord-
ing to the criteria of the World Health Organisation
(WHO): the passage of unusually loose or watery stools at
least three times within a 24-hour period [5]. According to
the Bristol Stool Form Scale, the aspect of the stool will
be defined as watery with no solid matter (type 7 stool
form) [24].
Patients who meet any of the following criteria will
not be eligible for participation in the study: at least one
episode of diarrhoeal disease in the month prior to ad-
mission, those taking an antiemetic or antidiarrhoeal
medication at the time of presentation, those who are
known to have short bowel syndrome, those with an
underlying chronic inflammatory gastrointestinal dis-
ease, those who are immunocompromised or immuno-
suppressed, those who are on prolonged steroid therapy
and those who are severely dehydrated (according to the
definitions of the WHO guidelines for the treatment of
diarrhoea) [5].
Inclusion of patients and informed consent
A physician at each participating centre will approach all
parents or guardians of patients who meet all the inclusion
criteria and none of the exclusion criteria after routine ad-
mission. Informed consent will be sought from parents or
guardians (Figure 1). If parents or guardians are indecisive
about enrolment, they will be given until 72 hours after dis-
ease onset to consider entry into the study, after which
point the patient will no longer be eligible.Study medication and quality control
The study medication (lyophilised L. acidophilus, manufac-
tured under the WHO good manufacturing process guide-
lines) will be purchased from Imexpharm Pharmaceutical
Joint Stock Corporation (Cao Lanh, Vietnam). This pro-
biotic is registered with the Vietnam Ministry of Health
(MOH) as a drug. The laboratories at Oxford University
Clinical Research Unit will perform internal quality control
of the medication before the start of the study. Sachets will
contain 1 × 109 CFU of L. acidophilus. Placebo sachets will
contain an excipient (maltodextrin) only. The manufacturer
will blind the contents of the sachets, and the master code
will be disclosed to the study pharmacist only.
Treatment groups and duration of treatment
All patients will receive the standard of care, according to
the national guidelines for the management of diarrhoealdiseases in children (Vietnam MOH, 2009), supplemented
with oral zinc (20 mg per day) for 10 days, according to the
WHO guidelines [5]. Subsequently, all patients will be ran-
domly assigned to one of the two study groups at a 1:1
ratio. As probiotics are widely used without adverse effects
and scientific publications indicate a variable beneficiary ef-
fect, the standard dose of study medication has been
increased to avoid underdosing. Therefore, one group of
participants will receive twice the standard daily dose of
L. acidophilus (4 × 109 CFU), and the other group of parti-
cipants will receive placebo. The regimes will be identical in
both study groups: doses every 12 hours for 5 days. For
each dose, two sachets of the study medication will be dis-
solved in 10 ml of water and will be administered orally to
participants by their parents or guardians. If the participant
vomits within 60 minutes of taking the drug, an additional
dose will be given (up to two extra doses in 4 hours).
Dosing and redosing will be recorded in the case report
form (CRF).
If participants require an antidiarrhoeal or antiemetic
medication, they will be categorised as a treatment fail-
ure and analysed accordingly. The prescription of any
additional treatment, including antimicrobials, will be
recorded in the CRF.
If treatment is discontinued because of an AE, the treat-
ing physician will record this and monitor the individual
until the AE has resolved or stabilised. Participants who
discontinue study treatment because of an AE will con-
tinue to be followed as per protocol. Physicians will dis-
charge participants after the completion of the 5-day
treatment course or 24 hours after the complete cessation
of symptoms, whichever occurs first. If participants are
discharged before completing the 5-day treatment course,
the parents or guardians will be asked to complete the ad-
ministration of all 10 doses. A follow-up visit at day 12 will
be planned with the parents or guardians of participants
upon discharge.Randomisation and blinding
The study pharmacist will create a computer-generated
block randomisation with blocks of varying size and stratifi-
cation by participating centre. The probiotic and placebo
sachets will be prepared in 5-day treatment packages plus
vomit doses as described below. These will be labelled in
advance and kept in a secure location. Participant numbers,
which correspond to a package of sachets, will be assigned
to each enrolled patient in strict numerical sequence. The
treatment packages will be dispensed according to the par-
ticipant number once a patient is enrolled into the trial. A
chronological log of all enrolled patients will be maintained,
and the next available sequential study code will be
assigned to patients as they enrol.
Figure 1 Trial study flow-chart.
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Data will be recorded on study-specific CRFs and sam-
ples will be collected from each participant as indicated
in Table 1. Briefly, after enrolment, study staff will per-
form the assessments, complete the appropriate CRF
sections and collect laboratory samples according to
protocol. Study medication will then be assigned. During
hospitalisation, daily assessments of the participants will
be performed and study staff will collect daily faecal
samples or rectal swabs. Once the treating physician has
deemed hospitalisation is no longer required, discharge
will be arranged, as well as a follow-up visit. On dis-
charge and at follow-up, assessments will be performed
and faecal samples collected.Sample handling and storage
Samples will be labelled with the patient study code
assigned at enrolment. The samples will be used for the
purpose of this study, as stated in the protocol, then
stored for future use. Consent will be obtained from par-
ticipants’ parents or guardians for sample storage and/or
shipment of specific samples to collaborating institutions
for investigations that cannot be performed locally.
Laboratory methods
During the study, all collected samples will be labelled as
stated in the protocol, stored at 4°C and transported to the
laboratory at the Oxford University Clinical Research Unit
within 24 hours. Routine haematology and biochemistry
Table 1 Clinical and laboratory data collection
Admission Daily Discharge Follow-
up
Physical examination ✓ ✓ ✓ ✓
Assessment of dehydration ✓ ✓ ✓ ✓
Assessment of diarrhoea ✓ ✓ ✓ ✓
Data collection ✓ ✓ ✓ ✓
Faecal sample ✓ ✓* ✓*
Faecal or rectal swab ✓ ✓* ✓*
Blood sample (3 ml)
(biochemistry/haematology
and viral polymerase chain
reaction)
✓
* If the participant cannot produce a stool sample on discharge, a faecal or
rectal swab will be collected instead.
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evaluate the severity of dehydration and disease.Bacteriology
Faecal samples will be cultured on blood agar, MacConkey
agar, xylose lysine desoxycholate agar, Campylobacter se-
lective media and selenite cystine broth (Oxoid Microbiol-
ogy Products; Thermo Scientific, Basingstoke, UK) to
detect Salmonella spp.), Shigella spp. and Campylobacter
spp. If pathogenic bacteria are suspected, isolation will be
performed on nutrient agar (Oxoid Microbiology Pro-
ducts), followed by identification by standard biochemical
reactions and API 20 E (bioMérieux, Marcy l’Etoile,
France). Antimicrobial susceptibility testing will be per-
formed on all pathogenic bacteria on Müller-Hinton agar
by disk diffusion for ampicillin (10 μg), amoxicillin/clavula-
nic acid (20/10 μg), ceftriaxone (30 μg), ceftazidim (30 μg),
ciprofloxacin (5 μg), nalidixic acid (30 μg), ofloxacin (5 μg),
gentamicin (10 μg), chloramphenicol (30 μg) and trimetho-
prim/sulfamethoxazole (23.75/1.25 μg; Oxoid Microbiology
Products). Erythromycin (15 μg) and clindamycin (2 μg)
will be added for Campylobacter spp. Zone diameters will
be interpreted according to the Clinical Laboratory
Standards Institute (CLSI) clinical breakpoints. Culture
results and antimicrobial susceptibility results will be
reported back to the treating clinicians.
Virology
Norovirus and rotavirus real-time reverse transcriptase
polymerase chain reaction (RT-PCR) will be performed on
total nucleic acid extracted from blood and faecal samples
collected on admission using a previously published
method [25]. Results will be reported to the treating clin-
ician and disclosed to the parents or guardians of the parti-
cipants. Aliquots of faecal samples collected at discharge
and during follow-up visits will be stored as 10% vol/vol
suspensions in phosphate-buffered saline at −80°C. Faecalor rectal swabs collected during hospitalisation will be
stored at −80°C in viral transport media. Norovirus and
rotavirus real-time RT-PCR will be performed in batches
retrospectively. Because this trial is exploratory, results will
be analysed for the patients who test positive for norovirus
and/or rotavirus at admission only.
Primary end point
The primary end point is the time from the first dose of
study medication to the start of the first 24-hour period
without diarrhoea as assessed by the nurse on duty.
Secondary end points
The following are the secondary end points:
1. The time from the first dose of study medication to
the start of first 24-hour diarrhoea-free period as
recorded by parents or guardians in an hourly
checklist, which will be collected by the nurses on
duty every 12 hours.
2. Treatment failure, defined as the occurrence of (a)
No resolution of diarrhoea after 5 days of treatment,
(b) severe symptoms for which treatment is stopped,
such as the development of severe dehydration, renal
failure, (septic) shock, respiratory distress or other
syndromes associated with diarrhoeal disease as
complications (e.g., pneumonia) [5]; and (c)
additional antiemetic (domperidone) or
antidiarrhoeal (aluminium silicate or racecadotril)
treatment.
3. The frequency of stools during the first 3 days after
the first dose of study medication.
4. The load in copies per millilitre of viral transport
medium of norovirus and rotavirus measured by
RT-PCR, assessed daily from admission until
discharge and at follow-up.
5. The duration of hospitalisation, defined as the
number of days from hospital admission until
discharge.
6. The extent of intestinal L. acidophilus colonisation,
assessed by analyses of faecal samples or rectal swabs
collected on admission, on discharge and at
outpatient follow-up for the first 50 participants who
agree to participate.
7. The number and severity of AEs.
Reporting of serious adverse events
All AEs and serious adverse events (SAEs) will be recorded
on the participant’s CRF. If a participant experiences a SAE,
defined according to International Conference on Harmon-
isation of Technical Requirements for Registration of
Pharmaceuticals for Human Use guidelines on clinical
safety data management, the treating physician will inform
the principal investigator and complete the specific CRF
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Data Safety Monitoring Board (DSMB), the research ethics
committees of reference and the Hospital Ethical Commit-
tee where the participant is admitted.
Sample size and statistical considerations
Data originating from three hospitals in Ho Chi Minh
City suggest that the median duration of hospitalisation
in our target population is 5 days (interquartile range
= 3 to 6 days; mean and standard deviation [SD] of log10
duration = 0.61 and 0.27, respectively) and an approxi-
mately normal distribution of the log-transformed data.
As we have limited preexisting data on the overall length
of diarrhoeal illness (prehospitalised and hospitalised),
and as children are usually discharged at the time of
resolution of diarrhoea, we used the variability of the
length of hospitalisation as the basis of our sample size
calculation using R software version 2.15.1. This study is
designed to test the hypothesis that probiotic therapy is
superior to placebo for the treatment of acute watery
diarrhoea. It is powered to detect a 20% decrease in the
duration of acute watery diarrhoea (corresponding to an
absolute effect size of approximately 24 hours) of twice
the standard dose of probiotics compared to placebo.
For 80% power with a two-sided 5% significance level, a
total of 123 participants per study group are required.
To account for potential inadequacies in our assump-
tions and some loss to follow-up, the sample size was
increased by 22%. Therefore, a total sample size of 300
participants (150 in each group) will be recruited.
Analysis and reporting
All randomised patients will be included in the analysis,
following the intention-to-treat principle. The comparison
of the primary end point will be performed on a per-
protocol population, which excludes participants who are
mistakenly randomised (in violation of the inclusion and
exclusion criteria) and those who withdraw or are lost to
follow-up prior to reaching the primary end point.
The primary end point will be compared between the
study arms on the basis of a lognormal accelerated
failure time regression model, which models the
log-transformed outcome as depending linearly on cov-
ariates plus a normally distributed error term for
unexplained variation [27]. It generalises the standard
linear regression model of the log-transformed outcome
to right-censored or interval-censored outcome data that
are required for analysing our primary end point. If par-
ents or guardians cannot specify the exact time of cessa-
tion of diarrhoea, then the assessment by the nurse on
duty who assesses the child every 12 hours will be used
instead (treated as an interval-censored outcome).
Children who are withdrawn or lost to follow-up be-
fore the cessation of diarrhoea will be treated ascensored on the day of withdrawal or loss. The primary
analysis will not adjust for any covariates, but, in a sec-
ond step, we will additionally explore the effect of the
following covariates on the duration of diarrhoea: dur-
ation of diarrhoea prior to enrolment, prior treatment
with antibiotics and prior treatment with probiotics, age
and diagnosed pathogen by culture or PCR. Likewise,
homogeneity of the treatment effect will be assessed
according to the subgroups defined by these. The sec-
ondary end point of the time from the first dose of study
medication to the start of the first 24-hour diarrhoea-
free period as assessed by the parents or guardians will
be analysed in the same way as the primary end point.
Other secondary end points will be compared between
the treatment arms on the basis of logistic regression for
binary data, Poisson regression for count data, linear re-
gression for continuous data and the lognormal acceler-
ated failure time model for time-to-event data. The
comparison of viral load outcomes for norovirus and
rotavirus detected by RT-PCR will be adjusted for the
participant’s baseline viral load to increase power.
The results of this trial will be reported in one or sev-
eral peer-reviewed publications.
Ethical approval
The protocol has been reviewed and approved by the
Oxford Tropical Research Ethical Committee in the
United Kingdom and will be submitted for review at the
ethical committees of the participating hospitals in
Vietnam.
Discussion
Diarrhoeal disease in young children remains common
in low- and middle-income countries such as Vietnam.
The main therapy for diarrhoea consists of ORS and
zinc, which are frequently supplemented with antimicro-
bials in severe cases with a suspected bacterial aetiology.
Our recent work corroborated findings pertaining to the
aetiology of diarrhoea and the accepted clinical practice
of treating children hospitalised with acute watery diar-
rhoea in Ho Chi Minh City. We found that more than
60% of paediatric diarrhoeal cases were due to rotavirus,
norovirus or a mixed infection with both (Phan Vu Tra
My et al., unpublished manuscript).
Probiotic products are frequently used for purposes
other than those for which they were originally commer-
cialised, namely, as medication instead of as food. The
use of probiotics outside medical settings is also com-
mon in Vietnam. Probiotic brands are available inexpen-
sively without prescriptions, and food products and
formula milk are frequently supplemented with probio-
tics. As shown by several studies demonstrating that mis-
identification is the predominant cause of microbial
mislabelling, there is a clear need for better quality
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discrepancies between labels and the actual microbial con-
tent [28,29]. Therefore, we considered the use of a pro-
biotic brand that is registered as a drug by the Vietnamese
Ministry of Health and is produced according to inter-
national standard practices. Furthermore, we intend to en-
sure the consistency of the study medication by
performing quality assessments at multiple time points
throughout the trial.
Published studies on the effect of probiotics in treating
acute watery diarrhoea in children have compared one or
more of the following end points: reduction of diarrhoea
duration, stool frequency, hospitalisation duration, virus in
faeces and evidence of colonisation of probiotic bacteria.
We will record all of these variables in an attempt to per-
form the most comprehensive study possible. Furthermore,
we have taken into account recently published recommen-
dations for future clinical trials using probiotics by the
International Scientific Association for Probiotics and
Prebiotics [30].
The nurse on duty will measure the reduction of diar-
rhoea duration after the start of treatment and the effect of
probiotics on the total duration of diarrhoea in 12-hour
intervals. As nursing staff assess patients at least every 12
hours, it is efficient to include the study assessments and
data collection at those points in time. Children who parti-
cipated in our previous cross-sectional study in three hospi-
tals in Ho Chi Minh City were discharged after a median of
5 days (range, 1 to 22 days). It is difficult to collect reliable
data on daily stool frequency after discharge; therefore, we
have chosen to analyse stool frequency only during the first
3 days of hospitalisation. It is imperative to have a labora-
tory measurement for the effect of probiotics on diarrhoea;
therefore, we have additionally selected the viral loads of
norovirus and rotavirus in faeces as a secondary end point,
as these organisms are the most common cause of acute
watery diarrhoea. Norovirus and rotavirus viraemia have
been described previously, and rotavirus antigenaemia has
been associated with rotavirus viraemia [31,32]. We have
also included an exploratory analysis on the load of noro-
virus and rotavirus in the blood of participants with the aim
of investigating viral presence and viral load in those who
test positive for norovirus or rotavirus in the stool. The abil-
ity of probiotics to colonise the intestinal tract is one of the
definitions of a probiotic [33]. Colonisation by probiotics is
reported to occur after several days of treatment and is
reported to be transient and last for an ill-defined time
period [34-37]. Hence, we have included a further
secondary end point investigating the colonisation of
L. acidophilus in faecal samples by culture and molecular
techniques before treatment, at discharge and at follow-up.
Positive effects of probiotics have been reported for
decades for a number of conditions. For acute diarrhoea,
studies have investigated a variety of organisms, of whichBacillus spp., Lactobacillus spp., Bifidobacterium spp.,
Streptococcus thermophilus and Saccharomyces cerevisiae
subtype boulardii, used alone or in combination, have
been studied most often. These supplements have been
used in a range of dosages and for differing treatment
durations. Most seem to have a positive effect on the re-
duction of duration of diarrhoeal infections. Recently,
several guidelines for probiotic and prebiotic use have
been published, covering a variety of diseases, probiotic
microorganisms and recommended doses based on the
available evidence [38-40]. Yet, it remains unclear which
probiotic should be used for the treatment of acute
watery diarrhoea in our setting. We have chosen a read-
ily available and commonly used brand in Vietnam, but
other preparations may show a different effect. Further-
more, we are undecided as to what the appropriate dose
should be for this indication in children. Only a limited
number of trials have been published investigating dose-
dependent effects of probiotics, with the suggestion that
higher doses shorten diarrhoeal duration [17,41,42]. A
meta-analysis by Van Niel et al. suggested a positive lin-
ear association between the dosage of Lactobacillus and
the reduction in diarrhoea duration, when the results
from eight studies reporting reduction in diarrhoea as
the outcome, comparing Lactobacillus treatment to pla-
cebo, were analysed [43]. In this trial, we will use just a
single dose of probiotic to compare to placebo; there-
fore, we will be unable to show a dose–response effect.
If results from the proposed trial demonstrate that
probiotics have an effect on the primary end point of
length of diarrhoeal illness, these will be used to design
a larger trial to investigate the effects of different probio-
tics, as well as potential dose-dependent effects in more
detail. In addition, we will investigate potential immuno-
modulating effects of a probiotic on acute watery infec-
tious diarrhoea by measuring immune markers such as
cytokines, antibodies (e.g., immunoglobulin A) and the
activity of natural killer cells [44,45]. Other treatments
may also influence the duration of diarrhoea, such as
ORS, zinc or antimicrobials, but these have been only
minimally investigated in our setting. By recording medi-
cation of the participants during hospitalisation, we will
be able to investigate potential associations. Finally, in
limiting our diagnostics to the most common bacterial
and viral causes of diarrhoea, we will not be able to ex-
haustively diagnose the aetiological agents of each diar-
rhoeal episode. Stool samples will be stored and will be
assayed retrospectively where required to detect add-
itional pathogens.
We aim to clarify some of the reservations surround-
ing probiotic therapy for treating acute watery diarrhoea
in hospitalised children in Vietnam. A reduction in dis-
ease duration or severity in this common disease will
have a dramatic effect on both the length of stay in the
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reduction would be beneficial for both the Vietnamese
health service (which subsidises a large portion of treat-
ment for children younger than 6 years of age) and for
the families of hospitalised patients, who sacrifice a con-
siderable amount of time and money to remain with
their children in the hospital. By providing evidence of a
positive, negative or absent effect of an oral preparation
of L. acidophilus on acute watery diarrhoea, clinical
practice in Vietnam might be changed to the routine
prescription of probiotics to children. The ultimate aim
of this change in clinical practice would be to reduce the
disease burden in Vietnamese children.Trial status
This study protocol for a proposed randomised con-
trolled trial has not started patient recruitment, pending
the decision of local ethical committees.
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